Analytical Pharmacology

分析药理学

基本信息

批准号：
10650446
负责人：
MICHELLE A RUDEK
金额：
$ 21.62万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-05-07 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10650446
关键词：
AIDS Malignancy Consortium Adult Amendment Analytical Chemistry Antineoplastic Agents Applications Grants Binding Proteins Biological Biological Assay Biological Markers Brain Neoplasms Cancer Center Support Grant Clinical Clinical Pharmacology Clinical Trials Comprehensive Cancer Center Coupled Data Analyses Dose Drug Kinetics Early Therapeutic-Clinical Trials Network Ensure Environment Faculty Floor Funding Grant Human Resources In Vitro Ions Laboratories Lead Letters Liquid Chromatography Liquid substance Malignant Neoplasms Manuscripts Metabolic Methods Ohio Oncology Peer Review Performance Pharmacodynamics Pharmacogenetics Pharmacology Pharmacology Shared Resource Phenotype Plasma Plasma Proteins Play Protocols documentation Publications Recommendation Reporting Research Research Design Resource Sharing Role Sampling Schedule Services Specimen System Toxic effect Validation analytical method anticancer research assay development clinical trial protocol cost effective design detector drug development drug discovery drug metabolism experimental study good laboratory practice instrument instrumentation ion mobility mass spectrometer member metabolic abnormality assessment method development pharmacologic pre-clinical preclinical development preclinical study programs protocol development response tool translational pipeline translational study

项目摘要

PROJECT SUMMARY/ABSTRACT The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Shared Resource (APSR) has offered state-of-the-art and cost-effective analytical chemistry and clinical pharmacology services to Members continuously since its inception in 1985. The APSR provides instrumentation and facilities in a 1,750 ft2 laboratory on the first floor of the SKCCC Bunting-Blaustein Cancer Research Building. The specific aims of APSR are to: 1) provide expertise in clinical trial and preclinical study design, with a focus on critical pharmacological endpoints; 2) provide state-of-the-art, Good Laboratory Practice-quality, cost-effective services to quantitate anticancer drugs and metabolites or biomarkers in biological fluids; and 3) provide exposure-response analysis and interpretation, with the long-term vision of providing decision tools for drug development in both the preclinical and clinical settings. The APSR houses four ultra-performance liquid chromatography instruments with one UV/Vis detector, three triple-stage quadruple mass spectrometers, one QTrap system with ion trap capabilities for more intricate drug metabolism studies, and one ion mobility spectrometer. The APSR analyzes ~3,600 samples/year, develops ~15 new methods involving ~30 analytes per year and serves 29 faculty members across six of the CCSG Programs (plus nonprogrammatically aligned), with the majority of the users having peer-reviewed funding. The APSR remains a critical component across the translational spectrum, providing services in analytical method development (two manuscripts), drug discovery (three manuscripts), preclinical studies (16 manuscripts), clinical trials (18 manuscripts), exposure- response analyses (five manuscripts) and three other manuscripts. The APSR has participated in the submission of 57 cancer-focused grants over five years (across all CCSG Programs); played a major role in the successful applications for the Johns Hopkins Early Therapeutics Clinical Trials Network (UM1), AIDS Malignancy Consortium (UM1) and Chesapeake-Ohio Pharmacokinetics Core for the ETCTN (U24); and serves as a second laboratory for the Adult Brain Tumor Consortium (UM1). The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design and data interpretation, and ensure that instrumentation is suitably maintained and utilized efficiently. SKCCC Managed Shared Resource Reporting Period: January 1, 2020 to December 31, 2020

项目摘要/摘要 Sidney Kimmel综合癌症中心（SKCCC）分析药理学共享资源（APSR）提供了最先进的和具有成本效益的分析化学和临床药理学服务自1985年成立以来，成员一直致力于成员。APSR在A中提供仪器和设施 SKCCC Bunting-Bunaustein癌症研究大楼一楼的1,750 FT2实验室。具体 APSR的目的是：1）提供临床试验和临床前研究设计方面的专业知识，重点是关键药理终点； 2）提供最先进的，良好的实验室实践质量，具有成本效益量化生物液中抗癌药物和代谢产物或生物标志物的服务； 3）提供曝光反应分析和解释，具有为药物提供决策工具的长期愿景临床前和临床环境的发展。 APSR容纳四种超强液体带有一个UV/VIS探测器的色谱仪器，三个三阶段四级质谱仪，一个具有离子陷阱功能的QTRAP系统，用于更复杂的药物代谢研究，一个离子迁移率光谱仪。 APSR分析约3,600个样本，开发约15种涉及约30个分析物的新方法每年为六个CCSG计划提供29名教职员工（加上非编程性对齐），大多数用户经过同行评审的资金。 APSR仍然是关键组成部分在整个翻译光谱中，提供分析方法开发（两个手稿），药物的服务发现（三个手稿），临床前研究（16个手稿），临床试验（18个手稿），暴露 - 响应分析（五个手稿）和其他三个手稿。 APSR参加了在所有CCSG计划中，提交了57个以癌症为中心的补助金；在约翰·霍普金斯早期治疗临床试验网络（UM1）的成功申请，艾滋病 ETCTN（U24）的恶性财团（UM1）和Chesapeake-Ohio药代动力学核心；和是成年脑肿瘤财团（UM1）的第二实验室。请求的CCSG资金将提供与测定开发，协议设计和数据相关的咨询服务的支持人员解释，并确保有效地维护和利用仪器。 SKCCC托管共享资源报告期：2020年1月1日至2020年12月31日